MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Precipio Operating Cycle 2011-2026 | PRPO
Annual Operating Cycle Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.8 | 67.2 | 58.2 | 78.2 | 90.1 | 115 | 196 | 57.7 | 67.7 | 166 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 196 | 49.8 | 94.6 |
Quarterly Operating Cycle Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.6 | 46.5 | 41.8 | - | 38 | 40.5 | 46 | - | 44.2 | 45.4 | 58.4 | - | 76.4 | 77.6 | 62.9 | - | 53.4 | 50.2 | 65.2 | - | 74.6 | 89.1 | 76.7 | - | 89 | 77.4 | 107 | - | 124 | 105 | 115 | - | 289 | 308 | 143 | - | 117 | 78.9 | 101 | - | 83.2 | 64.3 | 49.3 | 34.7 | 274 | 166 | 179 | 78 | 159 | 150 | 183 | 101 | 207 | 184 | 199 | 80.6 | 176 | 203 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 308 | 34.7 | 110 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
259 | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
202 | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
128 | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
143 | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
73.9 | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
198 | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
161 | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
329 | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
251 | $ 8.42 | -6.44 % | $ 239 M |  Israel |
 |
Lantheus Holdings
LNTH
|
121 | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
405 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
213 | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
102 | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
368 | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
81.5 | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
285 | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
244 | $ 1.36 | 2.26 % | $ 408 M | USA |